Koordinierungszentrum für Klinische Studien der Philipps-Universität Marburg

Publikationen - Archiv

2010 ||| 2009 ||| 2008 ||| 2007 ||| 2006 ||| 2005 ||| 2004 ||| 2003 ||| 2002 ||| 2001 ||| 1999


Käbel M, Reuss A, Bois A, Kommoss S, Kommoss F, Gao D, et al. The biological and clinical value of p53 expression in pelvic high-grade serous carcinomas. J Pathol 2010;222(2):191-8.

Dodel R, Spottke A, Gerhard A, Reuss A, Reinecker S, Schimke N, et al. Minocycline 1-year therapy in multiple-system-atrophy: effect on clinical symptoms and [(11)C] (R)-PK11195 PET (MEMSA-trial). Mov Disord 2010;25(1):97-107.

du Bois A, Herrstedt J, Hardy-Bessard AC, Müller HH, Harter P, Kristensen G, et al. Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer. J Clin Oncol 2010;28(27):4162-9.

du Bois A, Reuss A, Harter P, Pujade-Lauraine E, Ray-Coquard I, Pfisterer J. Potential role of lymphadenectomy in advanced ovarian cancer: a combined exploratory analysis of three prospectively randomized phase III multicenter trials. J Clin Oncol 2010;28(10):1733-9.

Kuchinke W, Ohmann C, Yang Q, Salas N, Lauritsen J, Gueyffier F, Leizorovicz A, Schade-Brittinger C, Wittenberg M, et al. Heterogeneity prevails: the state of clinical trial data management in Europe - results of a survey of ECRIN centres. Trials 2010;11:79.

Mackay HJ, Brady MF, Oza AM, Reuss A, Pujade-Lauraine E, Swart AM, et al. Prognostic relevance of uncommon ovarian histology in women with stage III/IV epithelial ovarian cancer. Int J Gynecol Cancer 2010;20(6):945-52.

Menzler K, Chen X, Thiel P, Iwinska-Zelder J, Miller D, Reuss A, et al. Epileptogenicity of cavernomas depends on (archi-) cortical localization. Neurosurgery 2010;67(4):918-24.


de Zwaan M, Zipfel S, Herzog W, Herpertz-Dahlmann B, Konrad K, Hebebrand J, Schade-Brittinger C, Schäfer H, Fichter M, Quadflieg N, Jacobi C, Herpertz S. [EDNET - eating disorders diagnostic and treatment network]. Psychother Psychosom Med Psychol. Mar-Apr 2009;59(3-4):110-116.

du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J. Role of Surgical Outcome as Prognostic Factor in Advanced Epithelial Ovarian Cancer: A Combined Exploratory Analysis of 3 Prospectively Randomized Phase 3 Multicenter Trials By the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO). Cancer. Mar 15 2009;115(6):1234-1244.

Harter P, Hahmann M, Lueck HJ, et al. Surgery for Recurrent Ovarian Cancer: Role of Peritoneal Carcinomatosis: Exploratory Analysis of the DESKTOP I Trial About Risk Factors, Surgical Implications, and Prognostic Value of Peritoneal Carcinomatosis. Annals of Surgical Oncology. May 2009;16(5):1324-1330.

Meier W, du Bois A, Reuss A, et al. Topotecan versus treosulfan, an alkylating agent, in patients with epithelial ovarian cancer and relapse within 12 months following 1st-line platinum/paclitaxel chemotherapy. A prospectively randomized phase III trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR). Gynecologic Oncology. Aug 2009;114(2):199-205.

Pfisterer J, du Bois A, Bentz EK, Kommoss F, Harter P, Huober J, Schmalfeldt B, Burchardi N, Arnold N, Hilpert F. Prognostic Value of Human Epidermal Growth Factor Receptor 2 (Her-2)/neu in Patients With Advanced Ovarian Cancer Treated With Platinum/Paclitaxel as First-Line Chemotherapy: A Retrospective Evaluation of the AGO-OVAR 3 Trial by the AGO OVAR Germany. International Journal of Gynecological Cancer. Jan 2009;19(1):109-115.

Rinke A, Müller HH, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. Oct 1 2009;27(28):4656-4663.

Stamelou M, Pilatus U, Reuss A, et al. In vivo evidence for cerebral depletion in high-energy phosphates in progressive supranuclear palsy. Journal of Cerebral Blood Flow and Metabolism. Apr 2009;29(4):861-870.

Wild B, Friederich HC, Gross G, Teufel M, Herzog W, Giel KE, de Zwaan M, Schauenburg H, Schade-Brittinger C, Schäfer H, Zipfel S. The ANTOP study: focal psychodynamic psychotherapy, cognitive-behavioural therapy, and treatment-as-usual in outpatients with anorexia nervosa--a randomized controlled trial. Trials. 2009;10:23.


Arnold R, Wilke A, Rinke A, Mayer C, Kann PH, Klose KJ, Scherag A, Hahmann M, Müller HH, Barth P. Plasma chromogranin A as marker for survival in patients with metastatic endocrine gastroenteropancreatic tumors. Clin Gastroenterol Hepatol. 2008;6(7):820-827.

Fotopoulou C, du Bois A, Karavas AN, Trappe R, Aminossadati B, Schmalfeldt B, Pfisterer J, Sehouli J. Incidence of venous thromboembolism in patients with ovarian cancer undergoing platinum/paclitaxel-containing first-line chemotherapy: an exploratory analysis by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group. J Clin Oncol. 2008;26(16):2683-2689.

Harter P, Reuss A, Pfisterer J, Pujade-Lauraine E, Ray I, du Bois A. The role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer. A project of the AGO-OVAR and GINECO - Prognostic factor surgical outcome in advanced ovarian cancer. Geburtshilfe Und Frauenheilkunde. Sep 2008;68:S9-S10.

Stamelou M, Reuss A, Pilatus U, et al. Short-term effects of coenzyme Q10 in progressive supranuclear palsy: a randomized, placebo-controlled trial. Mov Disord. 2008;23(7):942-949.


Belau A, Pfisterer J, Wimberger P, Kurzeder C, du Bois A, Sehouli J, Loibl S, Burchardi N, Vergote I, Wagner U. Randomized, multicenter, two-dose level, open-label, phase IIa study with the intraperitoneally infused trifunctional bispecific antibody catumaxomab (anti-EpCAM × anti-CD3) to select the better dose level in platinum refractory epithelial ovarian cancer. Journal of Clinical Oncology. 2007;25(June 20):5556.

du Bois A, Pfisterer J, Burchardi N, et al. Combination therapy with pegylated liposomal doxorubicin and carboplatin in gynecologic malignancies: a prospective phase II study of the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and Kommission Uterus (AGO-K. Gynecol Oncol. 2007;107(3):518-525.

Haake M, Mueller HH, Schade-Brittinger C, et al. German Acupuncture Trials (GERAC) for Chronic Low Back Pain: Randomized, Multicenter, Blinded, Parallel-Group Trial With 3 Groups. Arch Intern Med. 2007;167(17):1892-1898.

Hahmann M, Schuster S, Peters R, Butterfaß-Bahloul T. MedDRA-Kodierung von Studiendaten; in: Kongress Medizin und Gesellschaft 2007 – Abstractband,
Hrsg: Wichmann HE, Nowak D, Zapf A; Augsburg, 2007, S. 112.

Seifart U, Fink T, Schade-Brittinger C, et al. Randomised phase II study comparing topotecan/carboplatin administration for 5 versus 3 days in the treatment of extensive-stage small-cell lung cancer. Ann Oncol. 2007;18(1):104-109.


Deuschl, G.; Schade-Brittinger, C.; Krack, P.; Volkmann, J.; Schafer, H.; Botzel, K.; Daniels, C.; Deutschlander, A.; Dillmann, U.; Eisner, W.; Gruber, D.; Hamel, W.; Herzog, J.; Hilker, R.; Klebe, S.; Kloss, M.; Koy, J.; Krause, M.; Kupsch, A.; Lorenz, D.; Reuss, f. A randomized trial of deep-brain stimulation for Parkinson's disease. N Engl J Med. 2006;355(9):896-908.

Chen X, Heinze S, Iwinska-Zelder J, Reuss A et al. Risk factors for epilepsy in patients with cavernomas. Akt Neurol. 2006:33.

Deuschl G, Schade-Brittinger C, Krack P, et al. A randomized trial of deep-brain stimulation for Parkinson's disease. N Engl J Med. 2006;355(9):896-908.

du Bois A, Reuss A, Harter P, Meier W, et al. The role of lymphadenectomy in advanced epithelial ovarian cancer in patients with macroscopically complete resection of intraperitoneal disease. Int J Gynecol Cancer. 2006;16(S3):601; #0008.

du Bois A, Weber B, Rochon J, et al. Addition of Epirubicin As a Third Drug to Carboplatin-Paclitaxel in First-Line Treatment of Advanced Ovarian Cancer: A Prospectively Randomized Gynecologic Cancer Intergroup Trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study. Journal of Clinical Oncology. 2006;24(7):1127-1135.

Funck RC, Blanc J-J, Mueller HH, Schade-Brittinger C, Bailleul C, Maisch B. Biventricular stimulation to prevent cardiac desynchronization: rationale, design, and endpoints of the 'Biventricular Pacing for Atrioventricular Block to Prevent Cardiac Desynchronization (BioPace)' study. Europace. 2006;8(8):629-635.

Harter P, du Bois A, Hahmann M, et al. Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial. Ann Surg Oncol. 2006;13(12):1702-1710.

Knake S, Rochon J, Fleischer S, et al. Status Epilepticus after Stroke Is Associated with Increased Long-term Case Fatality. Epilepsia. 2006;47 Dec(12):2020-2026(2027).

Ohmann C, Speer R, Wittenberg M, Semler SC, Drepper J. Strategie und Ausbau der IT-Infrastruktur für die medizinische Verbundforschung in Deutschland; in: GMDS 51. Jahrestagung 2006 – Abstractband, Leipzig, 2006, S. 104-105.

Ozols RF, Bookman MA, du Bois A, Pfisterer J, Reuss A, Young RC. Intraperitoneal cisplatin therapy in ovarian cancer: comparison with standard intravenous carboplatin and paclitaxel. Gynecol Oncol. 2006;103(1):1-6.

Pfisterer J, du Bois A, Sehouli J, Loibl S, Reinartz S, Reuss A, Canzler U, Belau A, Jackisch C, Kimmig R, Wollschlaeger K, Heilmann V, Hilpert F. The anti-idiotypic antibody abagovomab in patients with recurrent ovarian cancer. A phase I trial of the AGO-OVAR. Ann Oncol. 2006;17(10):1568-1577.

Pfisterer J, Plante M, Vergote I, et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol. 2006;24(29):4699-4707.

Pfisterer J, Weber B, Reuss A, et al. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO. Journal of the National Cancer Institute. 2006;98(15):1036-1045.

Wittenberg M, Speer R, Kuchinke W, et al. Erreichung und Sicherstellung von Validierungsstandards in den Forschungsverbünden der Telematikplattform für Medizinische Forschungsnetze e.V. (TMF); in: GMDS 51. Jahrestagung 2006 – Abstractband, Leipzig, 2006, S. 193.


Arnold R, Rinke A, Klose KJ, et al. Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: a randomized trial. Clin Gastroenterol Hepatol. 2005;3(8):761-771.

Donner-Banzhoff N, Brucks U, Schade-Brittinger C, Muller H-H. Long-term benefits of a postgraduate programme in clinical epidemiology. The study programme ''clinical evaluation'' of the University of Marburg. Z Arztl Fortbild Qualitatssich. 2005;99(7):449-454.

du Bois A, Quinn M, Thigpen T, et al. 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Ann Oncol. 2005;16 Suppl 8:viii7-viii12.

du Bois A, Rochon J, Lamparter C, Pfisterer J. Das Qualitätsprogramm der AGO Organkommission OVAR (QS-OVAR): Versorgungsstruktur und Realität 2001. Zentralbl Gynäkol. 2005;127:9-17.

du Bois A, Rochon J, Lamparter C, Pfisterer J. Impact of center characteristics on outcome in ovarian cancer in Germany. Zentralbl Gynakol. 2005;127 Feb(1):18-30.

du Bois A, Rochon J, Lamparter C, Pfisterer J. Ovarialkarzinom - Versorgungsstruktur und -qualität in Deutschland 2001-2004. Frauenarzt. 2005;7:560-567.

du Bois A, Rochon J, Lamparter C, Pfisterer J. Pattern of care and impact of participation in clinical studies on the outcome in ovarian cancer. Int J Gynecol Cancer. 2005;15(2):183-191.

du Bois A, Rochon J, Lamparter C, Pfisterer J. Welchen Einfluss haben Klinikmerkmale auf die Prognose beim Ovarialkarzinom in Deutschland? Zentralbl Gynäkol. 2005;127(18-30).

du Bois A, Sehouli J, Lund B, et al. Paclitaxel-carboplatin-gemcitabine (TCG) as first-line treatment of ovarian cancer: a prospective multicentre phase II study (AGO-OVAR 8) followed by a prospectively randomized phase III GCIG Intergroup study (AGO-OVAR 9, GINECO-TCG, NSGO-OC-0102) compar. Int J Gynecol Cancer. 2005;15(Suppl.3):224-225.

Harder S, Fischer P, Krause-Schafer M, et al. Structure and markers of appropriateness, quality and performance of drug treatment over a 1-year period after hospital discharge in a cohort of elderly patients with cardiovascular diseases from Germany. Eur J Clin Pharmacol. 2005;60(11):797-805.

Harter P, du Bois A, Schade-Brittinger C, et al. Non-enrolment of ovarian cancer patients in clinical trials: reasons and background. Annals of Oncology. 2005;16 Nov(11):763-770.

Hilpert F, Harter P, Reinartz S, et al. Phase I/II trial of the anti-idiotypic monoclonal antibody CA125 in patients with recurrent epithelial ovarian, fallopian tube or peritoneal cancer. Journal of Clinical Oncology. 2005;23(S16):5018.

Nonnenmacher C, Dalpke A, Rochon J, Flores-de-Jacoby L, Mutters R, Heeg K. Real-time polymerase chain reaction for detection and quantification of bacteria in periodontal patients. J Periodontol. 2005;76(9):1542-1549.

Pfisterer J, Harter P, Canzler U, et al. The role of surgery in recurrent ovarian cancer. Int J Gynecol Cancer. 2005;15(S3):195-198.

Pfisterer J, Weber B, du Bois A, et al. Paclitaxel/Carboplatin (TC) vs. Paclitaxel/Carboplatin followed by Topotecan (TOP) in First-Line Treatment of Advanced Ovarian Cancer. Mature Results of a Gynecological Cancer Intergroup Phase III Trial of the AGO OVAR and GINECO. 2005;23(16S Part I of II):#5007.

Pujade-Lauraine E, du Bois A, Goupil A, et al. Epirubicin/ paclitaxel/ carboplatin (TEC) vs paclitaxel/ carboplatin (TC) in first-line treatment of ovarian cancer FIGO stages IIB-IV. Results of a randomized AGO-GINECO GCIG Intergroup phase III trial. Int J Gynecol Cancer. 2005;15(S3):221.

Schade-Brittinger C. Einbindung eines KKS in ein Comprehensive Cancer Center; Philipps-Universität Marburg, Symposium 2005.

Stuart G, Avall-Lundqvist E, du Bois A, et al. 3rd International Ovarian Cancer Consensus Conference: outstanding issues for future consideration. Annals of Oncology. 2005;16(S8):viii36-viii38.

Vermorken JB, Parmar MKB, Brady MF, et al. Clinical trials in ovarian carcinoma: study methodology. Annals of Oncology. 2005;16(S8):viii20 - viii29.


du Bois A, Fink D, Schroeder W, Muenstedt K, Schmalfeldt B, Emmons G, Pfisterer J, Wollschlaeger K, Meerpohl HG, Hahmann M, Harter P. Descriptive Evaluation of pre-operative Selektion KriTeria for OPerability in recurrent OVARian cancer (DESKTOP-OVAR). A study of the AGO Ovarian Cancer Study Group and the AGO Organkommission Ovar. 2004. Int J Gynecol Cancer 2004, 14 (Suppl.1), 17 Abstract # 055. IGCS 2004 Oral Presentation

Gropp M, Meier W, Rochon J, du Bois A, Kuhn W, Pfisterer J, Richter B, Wollschlaeger K. Topotecan versus Treosulfan beim rezidivierten Ovarialkarzinom: Ergebnisse der Studie Ovar 2.3 der AGO Studiengruppe Ovarialkarzinom. 2004.

Höglinger GU, Rissling I, Metz A, Ries V, Heinermann A, Prinz H, Spieker S, Deuschl G, Baum E, Oertel WH, "Enhancing Recognition of Early Parkinsonism in the Community," Movement Disorder, Vol. 19, No. 5, 2004, pp. 505-512.

Harter P, Schade-Brittinger C, Burges A, Wollschlaeger K, Gropp M, Pfisterer J, Schmalfeldt B, Huober J, Staehle A, du Bois A. AGO-OVAR 14: A retrospective study evaluating the reasons for non-participating in trials in patients with ovarian cancer (OC) treated in coordinating centres of the AGO Studiengruppe Ovarialkarzinom. 2004. J Cancer Res Clin Oncol 130 Suppl. 1: 2004.

Harter P, Schade-Brittinger C, Belau A, Sehouli J, Loibl S, Lueck HJ, Jackisch C, Schroeder W, Canzler U, Kimmig R. AGO-OVAR 14: A restrospective study evaluating the reasons for non-participating in trials in patients with ovarian cancer (OG) treated in coordinating centers of the AGO Ovarian Cancer Study Group. 2004. Proc Am Soc Clin Oncol 23 2004, Abstract # 5081.

Harter P, Hahmann M, Hasenburg A, Burges A, Loibl S, Gropp M, Huober J, du Bois A. AGO-DESKTOP-OVAR: Deskriptive Evaluation präoperativer Selektions-Kriterien für die Operabilität bei rezidiviertem Ovarialkarzinom. 2004. Arch Gynecol Obstet, 270, 2004, 2 FV-O 1.8.

Kuchinke W, Venesileas D, Wagner M, Peters R, Wittenberg M, Bratke T, Meissner C, Ohmann C. Evaluation der Anwendung und Nutzerzufriedenheit mit Electronic Data Capture an sieben Koordinierungszentren für Klinische Studien (KKS). GMDS Jahrestagung . 2004. Abstract


Schade-Brittinger C. Koordinierungszentren für klinische Studien. Kongress Klinische Studien in der Neurologie . 2003. Abstract

Wittenberg M. EDC-Software in akademischen Institutionen, MACRO am KKS Marburg. MEDICA . 2003.

Diener H.C., Weber R., Schade-Brittinger C, and et.al.. Klinische Studien im Bereich der Neurologie in Deutschland. 2004. Akt. Neurol. 2003; 30: 288-295.

Dodel, R., Spottke, A., Schade-Brittinger C, Prinz H, Wenning, G., Poewe, W., Oertel WH, and for the European MSA-Study Group, K. P. S.. Doppel-blinde, randomisierte, zweiarmige Studie zur Evaluierung der Wirksamkeit und Verträglichkeit von Minocyclin bei der Behandlung von Patienten mit Multi-System-Atrophie. Hamburger Neurologenkongress 2003. Abstract

Goerg, C., Cölle J, Goerg, K., Prinz H, and Zugmaier G. Spontaneous rupture of the spleen: ultrasound patterns, diagnosis and follow-up. Br J Radiol 76(910)[Oct], 704-711. 2003.

Haake M, Buch M, Schoellner, C., Goebel, F., Vogel M, Hausdorf, J., Zamzow, K., Schade-Brittinger C, Maier-Boerries O, Riemert, C., and Müller H-H. Extrakorporale Stosswellentherapie (ESWT) zur Therapie der Plantarfasciitis - Prospektive randomisierte placebokontrollierte Multicenterstudie. 67.Jahrestagung der Deutschen Gesellschaft für Unfallchirurgie, 89.Tagung der Deutschen Gesellschaft für Orthopädie und chirurgische Orthopädie . 2003. Meeting Abstract (DGOOC) 2003

Haake M, Müller H-H, Schade-Brittinger C, Prinz H, Basler, H., Streitberger, K., Schäfer H, and Molsberger, A.. The German multicenter randomized, partially blinded, prospective trial of acupuncture chronic low-back pain: a preliminary report on the rationale and design of the trial. J Altern Complement Med 9(5)[Oct], 763-770. 2003.

Haake M, Buch M, Schoellner, C., Goebel, F., Vogel M, Mueller, I., Hausdorf, J., Zamzow, K., Schade-Brittinger C, and Müller H-H. Extracorporeal shock wave therapy for plantar fasciitis: randomised, controlled multicentre trial. BMJ 327(7406)[Jul 12], 75. 2003.

Haake M, Schade-Brittinger C, Müller H-H, Prinz H, Basler, H., Donner-Banzhoff, N., Schäfer H, and Molsberger, A.. Acupuncture in chronic back pain. Background, development and design of the German Acupuncture trial (gerac-clbp). Z Orthop Ihre Grenzgeb 141(1)[Jan-Feb], 6-10. 2003.

Speer R, Kuchinke W, Meisner C, Schwabedissen M, Troost R, and Wittenberg M. Systemvalidierung in klinischen Studien - Erstellung eines Validierungspakets für die KKS und andere Verbünde. 2003. Informatik, Biometrie und Epidemiologie in Medizin und Biologie 34(3):368.


Leppek R, Alfke H, Heverhagen J, Geisz E, Wittenberg M, and Klose KJ. Durchblutungsquantifizierung mittels parametrisierter dynamischer Kernspintomographie des Unterschenkels – ein VICORA-Teilprojekt. Deutsche Röntgenkongress . 2002. Abstract


Schade-Brittinger C, Prinz H. "Modellprojekt Akupunktur" als Beispiel für die Kooperation mehrerer KKS. im Rahmen einer klinischen Studie. 2001. Informatik, Biometrie und Epidemiologie in Medizin und Biologie 32, 265-266.

Selbmann H`K, Albrecht J, Brosteanu O, Prager R, Schade-Brittinger C, Schmoor C, Troost R, Unnebrink K. Aktivitäten der Fachgruppe Qualitätssicherung der Arbeitsgemeinschaft der Koordinierungszentren für Klinische Studien. 2001. Informatik, Biometrie und Epidemiologie in Medizin und Biologie 32, 291.

Ohmann C, Kuchinke W, Schade-Brittinger C, Wittenberg M, Heller B, Troost R, Pommerening K, Schwabedissen M, Schlichthaar R, Roßner R, and Gerneth F. Fachgruppe "Datenmanagement/Telematik". 2001. Informatik, Biometrie und Epidemiologie in Medizin und Biologie 32, 241.

Haake M, Sattler A, Gross MW, Schmitt J, Hildebrandt R, Müller HH. Vergleich der extrakorporalen Stoßwellentherapie (ESWT) mit der Röntgenreizbestrahlung beim Supraspinatussehnensyndrom - Ein prospektiver randomisierter einfachblinder Parallelgruppenvergleich. 2001. Zeitschrift für Orthopädie 2001; 139:397-402.


Frank M., Klose KJ, Wied M., Ishaque N, Schade-Brittinger C, and Arnold R. Combination therapy with octreotide and alpha-Interferon: Effect on tumor growth in metastatic endocrine gastroenteropancreatic tumors. 1999. American Journal of Gastroenterology 1999;94(5):1381-7.